Finasteride and Sex Drive: What the Trials Found, and What Post-Finasteride Syndrome Still Cannot Prove

Does finasteride affect sex drive? Yes, in a way that is real and small. Across 15 randomized, double-blinded, placebo-controlled trials covering 4,495 men, finasteride carried a 1.66-fold risk of sexual side effects (95% CI 1.20 to 2.30). In a 2026 systematic review, sexual adverse events appeared in 1.9% to 6.7% of men on oral finasteride 1 mg against 0.9% to 3.9% of men on placebo, most of them mild and reversible after stopping. What happens to the men whose symptoms do not stop is a separate question, and the trial record is close to silent: of 34 hair-loss trials audited in 2015, none had adequate safety reporting. The drug is a legitimate suspect, the measured risk is small, and the persistence question has never been settled.

Figures from Lee et al. 2019 (PMID 30206635), Zlotowska et al. 2026 (PMID 42396141) and Belknap et al. 2015 (PMID 25830296).

"Is it the finasteride, or is it me?"

Search "finasteride sex drive" and two confident answers come back. One says the side effects are rare, mild and mostly in your head. The other says the drug can flatten desire permanently and the trials were built to hide it. The research supports neither at full volume.

The usual story: a man notices his hairline moving, gets finasteride 1 mg (sold as Propecia and widely as a generic), takes it for a few months, and notices that wanting sex has quietly stopped happening. He goes looking, lands in a forum where the worst version is the loudest, and books a nine-minute appointment already frightened.

Finasteride differs from statins and sex drive and blood pressure medication and sex drive in one way that matters to you: it acts on the hormone pathway behind male sexual development, so when desire drops after starting it, the drug is a reasonable first suspect. Our piece on what testosterone therapy does and does not deliver covers the other end of that pathway.

What the randomized trials found

The cleanest pooled answer is a 2019 meta-analysis in Acta Dermato-Venereologica. Lee and colleagues gathered 15 randomized, double-blinded, placebo-controlled trials covering 4,495 men treated for male-pattern hair loss with finasteride 1 mg a day or dutasteride 0.5 mg a day. Use of 5-alpha-reductase inhibitors carried a 1.57-fold risk of sexual side effects (95% CI 1.19 to 2.08).

Split by drug, finasteride came out at 1.66 (95% CI 1.20 to 2.30). Dutasteride came out at 1.37 (95% CI 0.81 to 2.32), an interval crossing 1.0, so that result did not reach statistical significance on a small set of studies.

A relative risk of 1.66 means treated men reported sexual side effects about two thirds more often than placebo men. It does not mean two thirds of men had them. A 2019 review in the Journal of the American Academy of Dermatology screened 5,497 articles across 11 systemic dermatologic medications and identified level 1 evidence for sexual adverse effects as a primary outcome in patients taking finasteride.

The same risk, written as percentages

A 2026 systematic review in Frontiers in Medicine collected the absolute rates. Zlotowska and colleagues synthesized 41 studies, 33 of them primary evidence. Across placebo-controlled trials of oral finasteride 1 mg, sexual adverse events were reported in 1.9% to 6.7% of treated men against 0.9% to 3.9% of placebo men, most mild and reversible upon discontinuation.

Read the blue pairs first. The treated and placebo ranges overlap on oral finasteride 1 mg, which is why the relative risk is 1.66 and not 5, and why men on placebo reported the same symptoms. Some share of what gets reported on this drug would have been reported without it.

Zero of 34 trials had adequate safety reporting

In 2015 Belknap and colleagues audited every published trial report of finasteride for male-pattern hair loss in JAMA Dermatology. They asked whether the trials measured harm well enough to support a conclusion.

Of 34 trials, none had adequate safety reporting. Nineteen were partially adequate, 12 inadequate, and 3 reported no adverse events at all. Funnel plots came out asymmetric toward lower odds ratios for sexual adverse effects, which the authors read as systematic underdetection. No report assessed the adequacy of blinding. Eighteen (53%) disclosed conflicts of interest and 19 (56%) received manufacturer funding. Safety evaluation ran one year or less in 26 of the 34 (76%), so a symptom defined by outlasting the drug could not be found in most of them.

The finding nobody quotes may matter most. In a repository of 5,704 men prescribed finasteride at 1.25 mg a day or less, only 31% met the inclusion criteria for the trials that supported approval, and 33% took it longer than a year. The authors conclude that the available toxicity information is very limited, of poor quality, and seems to be systematically biased. That does not say the drug is dangerous. It says nobody measured carefully enough to know.

Three kinds of evidence, three different questions

Most arguments about this drug hold up different kinds of evidence while answering different questions.

Every paper here, and the question it cannot reach.

Source	Design	Size	What it found	What it cannot answer
Lee 2019	Meta-analysis of placebo-controlled trials	15 trials, 4,495 men	Finasteride 1.66 (1.20 to 2.30); dutasteride 1.37 (0.81 to 2.32), not significant	Anything after the trial ends
Zlotowska 2026	Systematic review of absolute rates	41 studies, 33 primary	Oral 1 mg 1.9% to 6.7% against 0.9% to 3.9% placebo	How often symptoms persist
Belknap 2015	Audit of safety reporting quality	34 trials; 5,704 men	0 adequate, 19 partial, 12 inadequate; 76% ran a year or less	What a well-reported trial would have shown
Pompili 2021	Pooled rates plus meta-analysis of comparisons	Pooled reports	Depressive symptoms 3.33% against 2.54%; odds ratio 2.14 (1.40 to 3.27)	Direction of cause. Its sustained-dysfunction figure covers affected patients only
Mondaini 2007	Randomized counseling trial, drug concealed	120 randomized, 107 completed	43.6% of men told about side effects reported one or more, against 15.3% of men told nothing	Whether one report is expectation or drug. Different dose and condition
Cilio 2025	Narrative review of post-finasteride syndrome	No pooled sample	Describes symptoms after discontinuation and the controversy over recognition	How common it is, and what causes it

Post-finasteride syndrome, and what the evidence can and cannot show

Post-finasteride syndrome is the name given to symptoms that continue after a man stops the drug. A 2025 review in the International Journal of Impotence Research describes sexual symptoms, neuropsychiatric symptoms and physical changes appearing together, and examines the controversy over whether this is a distinct clinical entity. It reports contrasting data, symptoms that should not be dismissed, and a need for more research.

The reason is structural. The evidence comes from case reports, from pharmacovigilance databases that count reports without counting the people at risk, and from groups of men who found each other because they had the same problem. None of that can produce a rate, because a rate needs a denominator.

Reports have moved regulators at least once. A 2022 review in the Journal of Dermatological Treatment records that patient complaints and analysis of the FDA adverse-event database led to depression being added to the US label in 2011.

On mood there is a pooled figure. Pompili and colleagues put crude pooled rates of depressive symptoms at 3.33% (95% CI 3.22% to 3.44%) with finasteride against 2.54% (2.44% to 2.64%) without, and a meta-analysis of comparisons gave an odds ratio of 2.14 (1.40 to 3.27), both at P below 0.0001. That is an association drawn from pooled reports, so it carries no direction of cause, and losing your hair sits alongside low mood often enough to be part of the picture.

The same paper carries a figure that circulates without its caveat. Pompili reports the risk of sustained sexual dysfunction as high, at 60.1% (37.3% to 82.9%). That percentage comes from pooling reports of patients who were already affected, and it is not a rate among all men who take finasteride. Anyone quoting 60% as your odds is misreading the paper.

The nocebo study, and why it cuts both ways

In 2007 Mondaini and colleagues published a study in the Journal of Sexual Medicine that gets quoted more often than it gets read. They randomized 120 sexually active men with an enlarged prostate to finasteride 5 mg, concealed as an unnamed compound of proven efficacy, for one year. One group was counseled that it may cause sexual side effects and that these are uncommon. The other was told nothing. Everybody got the same drug.

One hundred and seven completed. Among the 55 who had been told, 43.6% reported one or more sexual side effects. Among the 52 told nothing, 15.3% did (P = 0.03). The authors conclude that ordinary practice looks like the informed group, and that this nocebo effect has to be accounted for.

Two guardrails before anyone uses that study as a weapon. This was 5 mg for an enlarged prostate, five times the hair-loss dose in a different population, so the percentages do not transfer to a 30-year-old on 1 mg. And nocebo describes reported rates in a group. It says nothing about whether one man's experience is real. Expectation inflates the numbers coming out of practice, poor safety reporting deflates the numbers coming out of trials, and no study has joined the two.

Topical finasteride, dutasteride, and the dose question

Topical finasteride at 0.25% was associated with sexual adverse events in 2.8% of men against 4.8% for oral finasteride in the same 2026 review. Those are single reported rates across mixed study designs, so read the gap as a direction. Less drug reaching the bloodstream is a plausible mechanism, and the switch is a prescriber's call.

Dutasteride is the other 5-alpha-reductase inhibitor and a stronger one. Its relative risk of 1.37 (95% CI 0.81 to 2.32) missed significance on a thin evidence base, and its absolute rates ran 4.1% to 12.0% against 4.0% to 5.0% on placebo. A non-significant result on few studies is uncertainty, and no evidence of safety.

Does minoxidil affect sex drive?

Minoxidil is the other common hair-loss treatment and belongs to a different drug class. It works on blood vessels and hair follicles and does not inhibit the enzyme behind the pathway that makes finasteride a suspect. None of the reviews on this page pooled sexual side effects for topical minoxidil, so there is no number here. Absence of a pooled figure is absence of evidence. If you switch and something changes, tell your prescriber.

If your desire dropped after starting finasteride

This one has a mechanism behind it, so the drug deserves a serious look. Take these in order, because the appointment will be short.

1. Write down when it started: the month you began the prescription, the month you noticed the change. A timeline is the most useful thing you can hand a doctor.
2. Book with the prescriber and say the words out loud in the first two minutes. These get skipped when they wait for the end of a visit.
3. Ask what the options are: a lower dose, the topical formulation at 2.8% against 4.8% for oral, or stopping. All three are the prescriber's call. Change nothing on your own.
4. Ask for mood to be looked at in the same visit. Pooled rates put depressive symptoms at 3.33% with finasteride against 2.54% without, and low mood flattens desire on its own terms, as depression and low libido covers.
5. Bring the rest of your medication list. Several classes carry their own sexual side effects: antidepressants and low libido and blood pressure medication and sex drive.
6. Ask for sleep, stress, alcohol and a testosterone level to be ruled in or out. If the labs come back unremarkable, normal labs and low libido is written for that position, and sleep, libido and testosterone covers the lever most men underrate.

The everyday levers, and where a botanical fits

Read this part first. If your symptoms have continued after stopping finasteride, that is a doctor's problem first, and no supplement belongs near it. If you are still taking the drug, the prescriber is the first call. NUUD's own label says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For many readers, that sentence is the whole answer.

Separate from anything clinical, a few ordinary things move desire in most people, and the free ones do the most work.

• Sleep, in quantity and quality, which has the most direct line to testosterone and to wanting anything at all.
• Care for your mood, taken as seriously as the hair.
• Movement you enjoy, alcohol kept honest, and stress with somewhere to go.
• Time with a partner, with no performance attached. The general version is in low libido in men, and the evidence on supplements sold for testosterone is in what testosterone supplements actually do.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general. It does nothing for hair, nothing for hormones, nothing for dihydrotestosterone, and nothing for the effects of any medication. It has no role in post-finasteride syndrome or in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If your doctor has read the label and has no objection, that is what our men's libido gummies are for. The same formula comes as a capsule. Talk to your doctor first and bring the label.

"Nothing is wrong with you"

One answer online says the side effects are rare, mild and mostly imagined. Another says the drug can end your sex life permanently. The research supports neither. Finasteride raises the reported rate of sexual side effects by about two thirds in relative terms and by a couple of percentage points in absolute terms, and most of those effects resolved after men stopped. The trials behind those numbers were short and reported harm poorly enough that an audit found none of the 34 adequate. Men whose symptoms outlasted the drug describe something real that nobody has counted.

If you have been quietly wondering whether you are broken: no. You noticed a change in your own body and went looking for an honest answer, and found a fight instead. Noticing was the correct move. The next one is an appointment with the prescriber, timeline in hand and the symptom said out loud early. Low libido in men walks through everything else that flattens desire in your thirties, most of which has nothing to do with your hairline.

Keep reading

• Does TRT fix low libido?
• Statins and sex drive
• Antidepressants and low libido
• Normal labs, low libido
• Sleep, libido and testosterone

Frequently asked questions

Does finasteride lower sex drive?
Yes, in a way that is real and small. Across 15 randomized, double-blinded, placebo-controlled trials covering 4,495 men, finasteride carried a relative risk of 1.66 for sexual side effects (95% CI 1.20 to 2.30). In absolute terms a 2026 systematic review reports sexual adverse events in 1.9% to 6.7% of men on oral finasteride 1 mg against 0.9% to 3.9% of men on placebo, with most events mild and reversible upon discontinuation. Those trials were short, and a 2015 audit found that none of 34 finasteride hair-loss trials had adequate safety reporting, so how long the effect lasts is far less certain than its size. If your desire dropped after you started, tell the prescriber.

What is post-finasteride syndrome, and is it real?
Post-finasteride syndrome is the name given to sexual, mood and physical symptoms reported as continuing after a man stops the drug, and whether it is a distinct clinical entity is openly contested in the medical literature. A 2025 review describes the reported symptoms and the controversy over recognition, and calls for a multidisciplinary research effort. The evidence behind it is case reports, pharmacovigilance data and self-selected groups of affected men, none of which can produce a rate, because there is no count of everyone who took the drug underneath those reports. Reports did drive one documented labeling change: depression was added to the US label in 2011. Symptoms that continue after stopping are a conversation for your prescriber.

Do the side effects go away when you stop?
In the trial evidence, mostly yes. The 2026 systematic review reports that most sexual adverse events in controlled hair-loss studies were mild and reversible upon discontinuation, while individual susceptibility varies. The limit on that reassurance is that 26 of 34 audited trials evaluated safety for one year or less, so persistence past that window was mostly outside what the trials could see. Reports of symptoms that continued after stopping exist and are unquantified. Do not stop or change your medication without your doctor, and take any symptom that outlasts the drug back to the prescriber.

Is topical finasteride or minoxidil safer for sex drive?
Topical finasteride at 0.25% was associated with sexual adverse events in 2.8% of men against 4.8% for oral finasteride in the 2026 systematic review, which points toward lower risk with less drug reaching the bloodstream. Those are single reported rates pooled across mixed study designs, so read the gap as a direction. Minoxidil belongs to a different drug class and does not inhibit the enzyme that converts testosterone to dihydrotestosterone, and none of the reviews on this page pooled sexual side effects for it. Both switches are prescriber decisions.

Should I take a supplement for sex drive while on finasteride?
Talk to the prescriber first. If your symptoms have continued after stopping the drug, that is a medical conversation before anything else. NUUD is a botanical supplement built around desire in general, and it does nothing for hair, hormones, dihydrotestosterone, or the effects of any medication, including finasteride. The label says to avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. If your doctor has read the label and has no objection, it is one small thing on the desire side.

References

1. Lee S, Lee YB, Choe SJ, Lee WS. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica. 2019;99(1):12-17. https://pubmed.ncbi.nlm.nih.gov/30206635/
2. Belknap SM, Aslam I, Kiguradze T, et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatology. 2015;151(6):600-606. https://pubmed.ncbi.nlm.nih.gov/25830296/
3. Zlotowska A, Jastrzab-Miskiewicz B, Krajewski PK. Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review. Frontiers in Medicine. 2026;13:1787706. https://pubmed.ncbi.nlm.nih.gov/42396141/
4. Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: A systematic review. Journal of the American Academy of Dermatology. 2019;81(1):163-172. https://pubmed.ncbi.nlm.nih.gov/30905792/
5. Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ. Risk of Depression Associated With Finasteride Treatment. Journal of Clinical Psychopharmacology. 2021;41(3):304-309. https://pubmed.ncbi.nlm.nih.gov/33814544/
6. Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? The Journal of Sexual Medicine. 2007;4(6):1708-1712. https://pubmed.ncbi.nlm.nih.gov/17655657/
7. Cilio S, Tsampoukas G, Morgado A, Ramos P, Minhas S. Post-finasteride syndrome, a true clinical entity? International Journal of Impotence Research. 2025;37(6):426-435. https://pubmed.ncbi.nlm.nih.gov/39953145/
8. Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Finasteride for hair loss: a review. Journal of Dermatological Treatment. 2022;33(4):1938-1946. https://pubmed.ncbi.nlm.nih.gov/34291720/

This article is for general education and is not medical advice. Finasteride is a prescription medication, and only a licensed clinician can prescribe, adjust, or discontinue it. Do not stop or change your medication without your doctor. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing hair loss, post-finasteride syndrome, depression, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement.